Business ethics 101 for the biotech industry by MacDonald, Chris, 1969-
Biodrugs 2004; 18 (2): 71-77CURRENT OPINION 1173-8804/04/0002-0071/$31.00/0
 2004 Adis Data Information BV. All rights reserved.
Business Ethics 101 for the Biotech Industry
Chris MacDonald
Department of Philosophy, Saint Mary’s University, Halifax, Nova Scotia, Canada
Biotechnology companies face ethical challenges of two distinct types: bioethical challenges faced onAbstract
account of the nature of work in the life sciences, and corporate ethical challenges on account of their nature as
commercial entities. The latter set of challenges has received almost no attention at all in the academic literature
or media. This paper begins to remedy that lacuna, examining ethical issues that arise specifically on account of
the status of biotech companies as commercial entities. The focus here is on three representative issues: product
safety, corporate social responsibility, and corporate governance. It is argued that each of these issues poses
particular ethical challenges for companies in the biotech sector. In the area of product safety, it is noted that
biotech companies face particular challenges in determining what counts as a ‘safe’ product, given the
contentious nature of what might count as a ‘harm’ in the biotech field. In the area of corporate social
responsibility, the adoption of a ‘stakeholder approach’ and an attempt to manage the social consequences of
products pose special challenges for biotech companies. This is due to the enormous range of groups and
individuals claiming to have a stake in the doings of such companies, and the trenchant controversies over just
what the social consequences of various biotechnologies might be. In the area of corporate governance, biotech
companies need to seek out and follow best practices regarding the ways in which information, authority, and
influence flow between a company’s shareholders, managers, and Board of Directors, if they are to avoid
duplicating the ethical and financial scandal that brought down ImClone. An important meta-issue, here – one
that renders each of these corporate ethical challenges more vexing – is the difficulty of finding the appropriate
benchmarks for ethical corporate behavior in a field as controversial, and as rapidly evolving, as biotechnology.
Three programmatic suggestions can be made: Firstly, scholars and others interested in the ethical performance
of the biotech sector must seek out and build opportunities for richer interdisciplinary collaboration. Secondly,
companies within the biotech sector must seek out expertise and build capacity and competency in dealing with
the corporate ethical issues that arise in their sector. Finally, companies in the biotech sector should explore the
opportunities for collective problem solving afforded by the existence of local, national, and international
industry associations such as the Biotechnology Industry Organization, BIOTECanada, and EuropaBio.
1. Torn Between Two Worlds there is a market, and (ii) thereby producing a profit for their
owners.
Companies in the biotechnology industry – like others in the
As inhabitants of two worlds, biotech companies face a double-life sciences – inhabit at once two different domains. On one hand,
barreled array of ethical issues. One set of issues stems from thebiotech companies are part of the healthcare system. The products
involvement of biotech companies in the life sciences and theand processes they develop often have as their aim the improve-
healthcare system; the kinds of ethical issues that most readilyment of human health, the lessening of human pain, and the
spring to mind when the topic of ethics in biotechnology arises.forestalling of human deaths. On the other hand, biotech compa-
These include the now-familiar front-page issues such as the moralnies are also commercial ventures. That is, they are legal entities
status of human gametes and human fetuses, the permissibility ofthat function by marshaling capital and human resources with the
germ-line genetic modification,[1] and whether cloning threatensinterrelated goals of (i) producing a product or service for which
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what it means to be human.[2,3] Also included under this general ness is to increase profits;[4] and (ii) the attempt to explain ways in
which businesses can honor the legitimate claims of shareholdersheading are further issues that are less likely to grab headlines, but
and other investors, while at the same time paying due attention tothat are none the less familiar to those with more than a passing
the needs and rights of customers, employees, and neighboringknowledge of bioethics, including issues related to research on
communities.human subjects (consent, harm-benefit ratios, etc.), confidentiali-
ty, and the effects of genetic information on the lives of individuals For whatever reason, business ethics issues that arise in the
and communities. field of biotechnology have received surprisingly little attention1.
For as long as biotechnology has been a question of publicA second set of ethical issues is faced by biotech companies on
concern, ‘ethical issues in biotechnology’ has been a topicaccount of their status as commercial ventures. Issues here include
‘owned’ by bioethics (and, to a lesser extent, by environmentalethics in marketing and advertising, workers’ rights (or labor
ethics). This has meant that a large number of ethical issues critical
relations more generally), environmental issues, issues related to
to the biotech industry, including product safety and corporate
corporate governance and investor relations, social accountability,
governance issues, have been effectively excluded from the agen-
and issues associated with carrying out business in foreign coun-
da because they are largely beyond the ken of bioethics, as that
tries. Of course there is, in this list, nothing unique to the biotech
field has traditionally been understood2.
industry: to an extent, biotech companies face the same ethical
At this point, individuals not familiar with the relevant academ-challenges as are faced by companies in any other sector of the
ic literature may be perplexed. ‘Bioethics’…‘business eth-economy. These issues comprise the field of business ethics — the
ics’ …what’s the difference? It’s all about ethics, isn’t it? Fairstudy of ethical issues that arise in commercial ventures of all
enough. The distinction is, to a degree, artificial – a question of an
kinds. But for biotech companies, business ethics has a somewhat
arbitrary distinction drawn between two academic disciplines. Yet
different flavor, or spin, owing to the uniqueness of the products
there is a significant degree of differentiation between the two
these companies produce and the services they provide.
fields. They are studied, for the most part, by different people.
The topic under discussion here is this second set of ethical They are written about in different journals, and in different books.
challenges, namely those that biotech companies face by virtue of But biotech spans the two. And a number of the specific ethical
their status as commercial enterprises. These challenges have issues that arise with regard to commercial biotechnology are in
historically proven particularly difficult for business ventures of fact quite foreign to the sorts of considerations and frameworks
all kinds. The scandals involving Enron, WorldCom, ImClone, that flow from the field of bioethics. So attending here to the
and others are among the more recent ‘sentinel events’ that have corporate ethical issues that arise in biotech is part of an attempt to
focused attention on corporate ethics. But a quick look at headlines fill a gap in our practical and theoretical understanding of the
over the past few decades reminds us of the many major news ethical challenges faced in that industry.
stories that turned into business ethics case studies: the Ford Pinto,
the Exxon Valdez, Dow Corning breast implants, and Union
2. Corporate Ethical IssuesCarbide’s disaster at Bhopal, to name a few. In each case, we see
evidence of corporate executives and other employees choosing
poorly when asked to choose between profit and ethics. But this In this section, three key issues of corporate ethics, namely
tension – between obligations to shareholders and obligations to product safety, corporate social responsibility, and corporate gov-
others – is not found only in these notorious cases. It is a tension ernance, are examined as they relate to biotechnology companies
endemic to the world of business. And the field of business ethics as commercial entities. In each case, the primary considerations
has historically had as its primary concerns: (i) the attempt to found in the business ethics literature are outlined, and the notable
refute the claim, most famously voiced by Nobel Prize-winning differences, if any, in the form that the issue takes within the
economist Milton Friedman, that the only responsibility of busi- domain of biotechnology versus in other industries are discussed.
1 An informal search by the author indicates that the two leading journals in the field of business ethics, namely the Journal of Business Ethics and
Business Ethics Quarterly, have between them published, over a 5 year period (1997 to August 2002), just seven articles related in some way to
biotechnology.
2 For more on the complementarity of business ethics and bioethics, see Ells & MacDonald.[5]
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2.1 Issue 1: Product Safety in a certain ethnic population, to a particular toxin. Brenkert’s
analysis suggests that the increasingly popular social products
liability doctrine would permit a company to be held responsibleThere is considerable literature on product safety, stretching
for such a use of its discoveries, even if the company had no directback at least several decades. The old standard of caveat emptor –
role in the terrorist acts in question.‘ let the buyer beware’ – is now generally recognized as defunct.
Brenkert’s second point is philosophical: he argues that there isCorporations are recognized as having a duty of care with regard
indeed good ethical grounding for this emerging legal standard,to both the obvious and the non-obvious safety-related aspects of
that is, the idea that a manufacturer might be morally responsibletheir products. This duty is recognized as extending well beyond
for distant harms caused by uses of a product remote from thethe requirements of law and regulation.[6] Of course, it is widely
manufacturer’s sphere of direct control. The implication is that therecognized that no product is without risk: almost any product, if
trend towards application of the stringent standard implied by theused wrongly, can result in injury. Because of this fact, “questions
social products liability doctrine is not just happening: it is indeedof safety are essentially questions of acceptable and known levels
happening for good reasons. Briefly, if companies produce aof risk”.[7] The operative question, then, is whether a given compa-
product that, in the current social context, may foreseeably con-ny has taken sufficient care to make sure that known risks asso-
tribute to undesirable outcomes, and if those companies makeciated with their products are made clear to consumers; and that
specific choices that contribute to, rather than mitigating, thosetheir product is reasonably free of dangerous defects. The question
harms, then it is at least prima facie reasonable that they be heldof what counts as ‘sufficient’ care is, of course, a difficult one, but
collectively responsible for (some portion of) the resultant harms.the concept at least provides a framework within which to evaluate
And with the weight of good reason on its side, the social productsthe extent of a corporation’s obligation.
liability doctrine can reasonably be expected to continue to gainMore recently, a higher standard has emerged within the litera-
ground. Of course, to say that there are good reasons to supportture with regard to the responsibility of manufacturers for their
this doctrine is not to conclude the debate. But the fact it is evenproducts. Brenkert[8] calls this the ‘social products liability’ doc-
advanced as plausible should make it clear that issues such astrine. According to this doctrine, the manufacturer of a product
whether a pharmacogenomics corporation should be held respon-may be held responsible for harms caused by that product, even if
sible for distant, marginally foreseeable consequences of its dis-the product is in no way defective and even if the harm caused was
coveries are precisely the sort of business ethics issues with whichnot the result of some activity over which the manufacturer had
biotech companies, and industry organizations, must increasinglydirect control. The particular focus of Brenkert’s own discussion is
develop competency.the putative responsibility of (at least some) gun manufacturers for
Indeed, for the field of biotechnology, product safety is a(at least some) deaths caused by their products. Brenkert argues
special concern, both ethically and strategically. No companythat, if such responsibility is plausible, it must be so because four
wants to face the public relations disaster that Monsanto encoun-conditions are met, namely: (i) significant harms have occurred;
tered in relation to the marketing of genetically modified seeds and(ii) the actions of gun manufacturers (e.g. in their marketing
foods.[9] This fear makes product safety management a crucialstrategies) contributed to those harms; (iii) those harms and their
strategic consideration. Beyond pragmatic questions of good pub-connection to the manufacturer’s marketing practices were fore-
lic relations, the ethics of product safety is an exceptionallyseeable; and (iv) there were alternative courses of action open to
challenging issue for biotech companies. Generally speaking,the industry and its member companies.
firms engaged in health research and the provision of health-Brenkert makes two key points about the social products liabili-
related products and services are seen as being subject to very highty doctrine. The first is observational. Brenkert observes that, as a
ethical standards. Nowhere are ethical and legal standards formatter of fact, manufacturers in many industries are being held to
product safety more exacting than in fields related to humanthis higher standard. The lesson for biotech companies is that,
health.rightly or wrongly, the possibility exists that corporations in the
biotech sector (to extend Brenkert’s own argument) might be held To complicate things further, it may be difficult – indeed,
responsible for the uses to which the technologies they develop are impossible – to define what counts as a ‘safe’ product in the field
put. For example, it might someday come about that a of biotechnology. At least some of the dangers attributed to
pharmacogenomics firm is held responsible for a terrorist act made genetically modified foods by opponents of those products are
possible by its discovery of a genetic susceptibility, concentrated dangers that are impossible to quantify and perhaps even difficult
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to define. Think, for example, of the claim that antibiotic-resis- The adoption of a stakeholder management perspective, as part
tance genes (sometimes used as markers of genetic transforma- of a CSR strategy, may pose particular challenges for biotech
tion) might spread from genetically modified plants to other or- companies. In particular, it can be very difficult to establish just
ganisms,[10] or the claim that cloning threatens what it means to be who should be counted among a biotech company’s stakeholders.
human.[2] The very measures according to which such risks should Indeed, this is a problem for stakeholder theory in general. A
be judged are the subject of serious debate. This difficulty, com- central question in the literature relates to whose interests should
bined with the growing significance of the social products liability have influence on managerial decisions, and how much? Biotech
doctrine, means that it may be exceedingly difficult for biotech companies face special challenges in this regard, as their stock-in-
companies in particular to seek out and follow appropriate stan- trade includes the very building blocks of all life – DNA, RNA,
dards and policies when it comes to product safety. stem cells, etc. At least some of their activities have implications
for (or are seen as having implications for) a very, very wide range
of ‘interested’ parties indeed. So the range of potential stakehold-2.2 Issue 2: Corporate Social Responsibility
ers very quickly expands to include every human being on the
planet, if not every living thing. Deciding how to pay appropriate‘Corporate social responsibility’ (CSR) is a catch-all phrase
attention to legitimate interests, without encumbering corporateoften used to indicate the general sense in which corporations have
decision-making and sliding into paralysis, constitutes a veryobligations to the communities of which they are a part. CSR is a
serious – and under-explored – challenge for biotech companies.multi-faceted (and contested) concept. We will focus on two of its
A second relevant facet of CSR has to do with a corporation’sfacets here.
willingness to attend to the social consequences of its products. InFirst, attention to CSR can be taken to imply a willingness to
this regard, the socially responsible investment movement, forattend to the needs of a wider range of stakeholders than has
example, has supported a move away from investment in suchhistorically been the case for business corporations in general.
socially problematic industries as the arms, tobacco, gambling,According to adherents of what has come to be known in business
and alcohol industries. For many, the concern about these indus-circles as ‘stakeholder theory’, stakeholders are “those groups who
tries is not about individual instances of consumers using thesecan affect, or who are affected by, the activities of the firm”.[11]
products. The worry, rather, is that these industries are producingStakeholder theory (or, more generally, the stakeholder approach)
products that, when used by millions of customers, may haveseeks substantive ways to acknowledge that a wider range of
socially undesirable effects. That is, the social consequences ofparties are crucial to the success of the firm, and that many of these
widespread smoking, drinking or gambling may include harms notparties might in fact be owed serious, concrete, moral obligations.
captured by examining individual behavior.The stakeholder approach – at least, those elements that suggest
Corporations can attend to the social consequences of theirthat attention to a broad range of stakeholders is not merely wise
products and services in a number of ways. Some companies takebut morally mandatory – has become enormously popular, if
action to mitigate the acknowledged negative social implicationssomewhat contentious. Critics charge that the multiple lines of
of their products. Some tobacco companies, for example, nowaccountability implied by acknowledging a multiplicity of stake-
produce anti-smoking literature aimed at teens. Other companiesholders reduces efficiency,[12] and that indeed the very idea of
refuse entirely to sell certain products or services. Case in point:stakeholders as morally significant undermines the morally-signif-
many American sporting-goods retailers now refuse to sell fire-icant relationship between corporate executives and stockhold-
arms. And hospitals, in many jurisdictions, refuse to permit fetalers.[13] Critics also note that the stakeholder approach is incapable
sex-selection, on the grounds that the associated devaluation ofof guiding necessary improvements in corporate governance.[14]
females (given that female fetuses are more often aborted in suchThe financial catastrophes at Enron, WorldCom, and ImClone
scenarios) is socially pernicious.were all failures of corporate governance – that is, failures of the
way organizations and institutional incentives were structured, Attending to the social consequences of their products poses
resulting in failures of corporate behavior to align with corporate special challenges for biotech companies, because the social con-
goals and policies. Such failures will surely not be made less sequences of many biotech products and services are the subject of
likely, according to critics of stakeholder theory, if lines of ac- serious debate. For example, many biotech companies, as well as
countability are multiplied. (Norman and Heath, unpublished man- many scientists, have already foresworn one significant biotech-
uscript).[15] nology, namely reproductive cloning. For these companies and
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scientists, as well as for a very significant proportion of the general But the ImClone scandal was, in a sense, relatively minor; the
public, the social consequences (however ill defined) of cloning costs to the public were ‘merely’ financial. But in the field of
are simply unacceptable. So with regard to cloning, industry and biotech, it’s easy to imagine failures in governance with much
the public are (generally) on the same page. But other topics more worrisome consequences, both for public safety and for the
engender greater disagreement. The social implications of ad- long-term reputation of the industry. Imagine, for example, a CEO
vanced assisted reproductive technologies (and the special burden of a biotech company engaged in the development of a new form
they represent for women), or of the development of drugs of gene therapy, deciding to slant (or even falsify) data submitted
targeted to specific privileged (or under-privileged) ethnic groups, to the relevant regulatory bodies. Imagine the Board knowing
are as yet unclear. Biotech companies wishing to be socially about this, and failing to rein in the rogue CEO, because members
responsible, in the sense of attending to the social implications of of the Board stand to profit from the short-term inflation of stock
their products and services, face serious challenges, not the least of prices that would follow regulatory approval of the new therapy.
which is determining just what the social implications of those Such a failure of corporate governance – rooted at least partly in
products and services are (or may one day be). faulty structuring of Board compensation – could have disastrous
consequences both for patients and for stockholders.
Governance issues won’t necessarily look dramatically differ-2.3 Issue 3: Corporate Governance
ent at biotech companies than at other companies. Two factors do
warrant mention, however. First, many biotech companies areThe Enron and Arthur Andersen scandals brought the question
founded by scientist-entrepreneurs, many of whom won’t have aof corporate governance into the limelight. Indeed, there is reason
detailed knowledge of management, let alone knowledge of state-to expect that corporate governance will be the key paradigm for
of-the-art corporate governance structures, or the niceties of secur-both the theory and practice of business ethics for at least the next
ities regulations. Secondly, the rate of change and the financialseveral years. Corporate governance systems are, roughly speak-
pressures of the biotech industry may encourage companies toing, the systems by which corporations are directed and controlled.
play fast-and-loose with the rules. The short timeline often experi-Such systems include the policies and procedures that determine
enced from making a scientific discovery (perhaps at a universityhow information, authority, and influence flow between a com-
lab), forming a spin-off commercial enterprise, acquiring venturepany’s shareholders, managers and Board of Directors. From the
capital and making an Initial Public Offering, through to productpoint of view of business ethics, governance is about who has the
development and commercialization, may simply be inconsistentright to determine the appropriate courses of action for a corpora-
with careful planning of governance structures. Slowing downtion, and how that right gets translated into actual corporate
long enough to find clarity about how best to direct the business ofbehavior.
the company in the interests of stockholders (with suitable atten-The biotechnology industry had its own high-profile brush with
tion to the public good) may not be easy, but it is nonethelessgovernance issues in the ImClone scandal. In October 2002,
crucial.Samuel Waksal, founder and former CEO of ImClone Systems,
pleaded guilty to criminal charges including securities fraud, per-
jury, bank fraud, and obstruction of justice. In short, Waksal had 3. Searching for Guidance: Ethics Benchmarking in
used his knowledge of an impending negative decision by the US the Biotech Industry
FDA concerning ImClone’s new cancer drug, cetuximab, to profit
Perhaps the most general way of describing the ethical chal-in ways forbidden by American securities regulations. The crimi-
lenge faced by companies in the biotech industry is by reference tonal charges laid point to individual culpability; but the real lesson
the notion of benchmarking.for the biotech industry lies in the larger failure of corporate
governance evidenced at ImClone. ImClone’s Board of Directors, Benchmarking is the process of determining who within a given
for example, whose role it is to represent and protect the interest of field is the very best, who sets the standard for excellent perform-
shareholders, failed miserably at this task when they turned a blind ance, and what that standard is. As it pertains to corporate ethics,
eye to Waksal’s forgery and fraud. Once they got wind of the benchmarking involves assessing hot key issues and surveying
trouble that was brewing, the members of the Board sold enough one’s industry and relevant stakeholders to determine which com-
shares to devalue ImClone’s publicly-traded stock, just prior to the panies are ‘getting it right’. In this regard, biotech companies face
FDA’s critical decision. a very serious ethical challenge. It is difficult, if not impossible, to
 2004 Adis Data Information BV. All rights reserved. Biodrugs 2004; 18 (2)
76 MacDonald
determine within the field of biotech who sets the standard and 4. Conclusion
what that standard is. The simple reason is that within biotech,
standards of ethical performance are even more hotly contested The goal of the present paper has been to introduce readers to a
than they are in other, more traditional industries. set of ethical challenges that biotech companies face not by virtue
of their status as life-science enterprises, but by virtue of theirWhere can biotech firms look to for the relevant benchmarks? It
status as commercial enterprises. No claim has been made thatseems trite at this juncture to point out that the science of biotech-
biotech companies are fully unique in this regard; the claim hasnology is advancing so rapidly that legal and ethical frameworks
merely been that, to date, too much discussion about ethical issuescan scarcely keep pace. None the less, it is of course not entirely
in biotechnology has been carried out with disregard for the facttrue to say that corporate decision-making takes place in a vacu-
that biotech research, development, and commercialization is oft-um; indeed, there exists a fairly wide range of national and
en done in a corporate context. To the extent to which the corpo-international guidelines that, in some sense or another, govern the
rate context has been noted in the literature on biotech ethics, suchbiotech industry. Noteworthy examples here include international
attention has generally been limited to cynicism about corporate
treaties such as the International Treaty on Plant Genetic Resour-
motives. This is not surprising: in the decade of Enron,
ces for Food and Agriculture,[16] the Convention on Biological
WorldCom, and ImClone, scholars, journalists, and indeed the
Diversity,[17] and the World Trade Organization (WTO) Agree-
general public may be forgiven for a degree of skepticism. But
ment on Trade-Related Aspects of Intellectual Property.[18] Bi-
skepticism is where enquiry begins; in itself, it does not solve hard
otech companies are also subject to various bits of national legisla-
problems.
tion. For example, Canadian biotech companies are subject to such
The first three quarters of a decade of intensive public attention
pieces of Canadian legislation as the Patent Act,[19] the Plant
to the world of biotechnology (beginning roughly with the birth of
Breeders’ Rights Act,[20] and, provided it passes the necessary
Dolly, the world’s first cloned mammal, in 1996) was dominated
parliamentary hurdles, the new Act Respecting Assisted Human
by discussion of bioethical issues. Is cloning ‘unnatural’? Is germ-
Reproduction (expected to be made law sometime during
line gene therapy too dangerous? When does human life begin? Is
2004).[21] Finally, biotech companies may also be subject to (or
individual consent to genetic testing for familial diseases suffi-
perhaps, more accurately, guided by) the industry’s own guide-
cient? The next decade will see – indeed, must see – increased
lines, as embodied in the Statement of Ethical Principles adopted
attention to corporate ethics in the world of biotech. As biotech
by the Biotechnology Industry Organization (BIO)[22] and BIOTE-
moves from a realm of speculative science to a realm of serious
Canada,[23] and EuropaBio’s Statement of Ethical Values.[24]
commercial enterprises, ethical reflection on that realm must shift
So, on the face of it, it would be false to say that the biotech as well. In a world of commercial biotechnology, questions of
industry lacks guidance. But still, it seems fair to suggest that there corporate ethics, including questions related to product safety,
is not much ethical certainty in this area. International conventions CSR, and corporate governance, will increasingly come to domi-
on biotechnology are open to – indeed, they are in need of – nate the field of biotech ethics.
national and local interpretation and contextualization. National Once we are collectively aware of this second set of ethical
laws such as Canada’s Patent Act are notorious for the awkward- challenges, and the vast body of related literature made available
ness with which their terms apply to the living things that make up by scholars in the field of business ethics, what way forward is
the biotech industry’s stock in trade. And although the industry is available? I conclude with three brief and programmatic sugges-
to be applauded for having taken steps to develop its own guide- tions.
lines, those guidelines are far from providing precise roadmaps Firstly, scholars and others interested in the ethical perform-
through treacherous moral terrain. So extant industry-wide ethics ance of the biotech sector must seek out and build opportunities for
guidelines, while a step in the right direction, will not always richer interdisciplinary collaboration. Biotech is already a richly
provide adequate direction. Given the fact that public opinion interdisciplinary field; biotech ethics is even more so. Yet the
regarding the moral standing of various biotechnologies is argument here suggests that including scholars from the field of
mercurial and often ill-informed, and that the opinion of experts in business ethics will return greater dividends still.
law and ethics is similarly deeply divided, one can be forgiven for Secondly, companies within the biotech sector must seek out
wondering where even well-intentioned biotech companies can expertise and build capacity and competency in dealing with the
look to for reliable guidance. corporate ethical issues that arise in their world. Enhancing capa-
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7. Velasquez MG. Business ethics: concepts and cases. 5th ed. Upper Saddle Rivercity in this regard will not ensure that a company does not become
(NJ): Prentice Hall, 2002
the next ImClone. It may help, however, to ensure that when the
8. Brenkert GG. Social products liability: the case of firearms manufacturers. Bus
light of public scrutiny is cast its way, the reasons that a company Ethics Q 2000; 10 (1): 21-32
is able to give for the decisions it has made will be better, richer, 9. Dhanda RK. Guiding Icarus: merging bioethics with corporate interests. New
York: Wiley-Liss, 2002and more well thought-out ones.
10. Health risks of genetically modified foods [editorial]. Lancet 1999 May 29; 353Finally, companies in the biotech sector should explore the
(9167): 1811
opportunities for collective problem solving afforded by the exis-
11. Freeman RE. Strategic management: a stakeholder approach. Boston (MA): Pit-
tence of local and national industry associations such as BIO, man Press 1984
BIOTECanada, and EuropaBio. Such organizations may well have 12. Beausang F. Democratising global governance: the challenges of the world social
forum [discussion paper no. 59]. Paris: Unesco/MOST, 2002. Available fromthe resources, the motivation, and the public legitimacy to develop
URL: http://www.unesco.org/most/dsp59_en.pdf [Accessed 2004 Jan 15]standards and corporate ‘best practices’ in ways beyond what is
13. Marcoux AM. Business ethics gone wrong: CATO policy report. Washington, DC:possible for individual companies. To date, such organizations
CATO Institute, 2000 Jul 24; 22 (3): 10-12
have done too little. But in a competitive domain beset by ethical
14. Sternberg E. Corporate governance: accountability in the marketplace. London:
uncertainty, they seem as good a hope as any for finding creative, Institute of Economic Affairs, 1998
shared solutions that are both mindful of the economic realities, 15. Norman W, Heath J. Stakeholder theory: governance and public management:
what can the history of state-run enterprises teach us in the post-Enron era?and at the same time socially responsible.
University of Montreal (unpublished manuscript)
16. International Treaty on Plant Genetic Resources for Food and Agriculture[online].
Available from URL: http://www.fao.org/ag/cgrfa/itpgr.htm [Accessed 2004Acknowledgements Feb 11]
17. Convention on Biological Diversity [online]. Available from URL: http://www.bi-
odiv.org/conention/articles.asp [Accessed 2004 Feb 11]This research was supported in part by a grant from the Nova Scotia Health
18. Agreement on Trade-Related Aspects of Intellectual Property [online]. AvailableResearch Foundation, and a New Faculty grant from Saint Mary’s University.
from URL: http://www.wto.org/english/tratop_e/trips_e.htm [Accessed 2004The views expressed here are those of the author, and not necessarily those of
Feb 11]these organizations. Thanks to Bryn Williams-Jones, Wayne Norman and
19. Patent Act. R.S.C. 1985, c. P-4Rahul Dhanda for helpful comments. Special thanks also to three supportive
anonymous reviewers for this journal, for their many thoughtful suggestions. 20. Plant Breeders’ Rights Act. R.S.C. 1990, c. 20
21. Respecting Assisted Human Reproduction [online]. Available from URL: http://
www.parl.gc.ca/PDF/37/2/parlbus/chambus/house/bills/government/
C-13_3.pdf [Accessed 2004 Feb 11]
References
22. Biotechnology Industry Organization. Bioethics statement of principles [online].
1. McKibben B. Enough: staying human in an engineered age. New York: Times
Available from URL: http://www.bio.org/bioethics/principles.asp [Accessed
Books, 2003
2004 Jan 15]
2. Baird PA. Should human cloning be permitted? Ann R Col Physicians Surg Can
23. BIOTECanada. About BIOTECanada -ethics [online]. Available from URL: http://2000; 33 (4): 235-7
www.biotech.ca/EN/ethics.html [Accessed 2004 Jan 15]
3. MacDonald C. Yes, human cloning should be permitted. Annals R Coll Physicians
Surg Can 2000; 33 (7): 437-8 24. EuropaBio. Ethical values [online]. Available from URL: http://ww-
w.europabio.org/pages/ev/ev_english.asp [Accessed 2004 Jan 15]4. Friedman M. The social responsibility of business is to increase its profits. N Y
Times Mag 1970 Sep 13: 122-126
5. Ells C, MacDonald C. Implications of organizational ethics to healthcare. Healthc
Correspondence and offprints: Dr Chris MacDonald, Department of Philoso-Manage Forum 2002 Fall; 15 (3): 32-8
phy, Saint Mary’s University, Halifax, NS, B3H 3C3, Canada.6. Shaw WH, Vincent B. Moral issues in business. 8th ed. Belmont (CA): Wad-
sworth, 2001 E-mail: chrismac@ethicsweb.ca
 2004 Adis Data Information BV. All rights reserved. Biodrugs 2004; 18 (2)

